The lawsuit, filed by Robbins LLP, claims that Insulet maintained defective manufacturing controls that created significant risks of insulin under-delivery and potential patient harm. According to the complaint, these internal deficiencies were obscured from the public, leading investors to purchase shares at artificially inflated prices throughout the specified period.

The market reacted sharply to disclosures regarding these manufacturing lapses. Following a March 2026 announcement of a voluntary Medical Device Correction for specific Omnipod 5 lots, Insulet shares dropped 6.88%. A second correction in May 2026, which expanded to include Omnipod DASH and Omnipod Eros systems, triggered a further 5.07% decline in the company’s stock price.

Investors who suffered losses during the class period have until August 31, 2026, to file for appointment as lead plaintiff. While those who do not serve as lead plaintiffs may still be eligible to participate in any potential future recovery, they must meet the eligibility criteria established by the court. The litigation highlights concerns regarding corporate transparency and the accountability of medical device manufacturers in maintaining rigorous safety standards.